Immatics (IMTX) Current Deferred Revenue (2019 - 2025)
Immatics (IMTX) reported Current Deferred Revenue of $21.6 million for Q4 2025, down 43.75% on a YoY basis from $38.4 million in Q4 2024, and down 27.78% sequentially from $29.9 million in Q3 2025.
Immatics (IMTX) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Current Deferred Revenue data on file, last reported at $21.6 million in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue fell 43.75% year-over-year to $21.6 million; the trailing twelve-month figure through Dec 2025 stood at $21.6 million (down 43.75% YoY), and the FY2025 full-year result was $20.9 million, down 46.1% from the prior year.
- Current Deferred Revenue declined to $21.6 million in Q4 2025, from $29.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $124.3 million in Q4 2023 to a low of $21.6 million in Q4 2025.
- A 5-year average of $70.2 million and a median of $71.5 million in 2021 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue jumped 87.56% in 2023 and plunged 70.74% in 2025, its largest moves.
- Tracing IMTX's Current Deferred Revenue over 5 years: stood at $57.7 million in 2021, then gained by 14.94% to $66.3 million in 2022, then jumped by 87.56% to $124.3 million in 2023, then tumbled by 69.13% to $38.4 million in 2024, then tumbled by 43.75% to $21.6 million in 2025.
- Business Quant data shows IMTX's Current Deferred Revenue at $21.6 million in Q4 2025, $29.9 million in Q3 2025, and $31.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Sep 30, 2025 | 29.88 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | 75.70 Mn |
| Jun 30, 2024 | 102.87 Mn |
| Mar 31, 2024 | 104.86 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Sep 30, 2023 | 67.55 Mn |
| Jun 30, 2023 | 74.04 Mn |
| Mar 31, 2023 | 70.07 Mn |
| Dec 31, 2022 | 66.27 Mn |
| Sep 30, 2022 | 104.07 Mn |
| Jun 30, 2022 | 123.05 Mn |
| Mar 31, 2022 | 47.14 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 72.97 Mn |
| Jun 30, 2021 | 74.91 Mn |
| Mar 31, 2021 | 86.50 Mn |